Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase

Artificial Organs

Volumn 39, Issue 9, 2015, Pages 741-747

  Ponce, Daniela ^a   Mendes, Marcela ^a   Silva, Tricya ^a   Oliveira, Rogerio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alteplase; Hemodialysis; Thrombosis; Tunneled central venous catheter

Indexed keywords

BLOOD VESSELS; CATHETERS; DIAGNOSIS; DIALYSIS; HEMODIALYZERS; MULTIVARIANT ANALYSIS;

ALTEPLASE; COHORT STUDIES; DIABETIC NEPHROPATHY; HAEMODIALYSIS; HEMODIALYSIS PATIENT; MECHANICAL; MULTI VARIATE ANALYSIS; PROSPECTIVES; RISK FACTORS; TUNNELED CENTRAL VENOI CATHETER;

DISEASES;

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; CATHETER REMOVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETERIZATION; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; INFECTIOUS COMPLICATION; INTERNAL JUGULAR VEIN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT TRANSPORT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; ADVERSE EFFECTS; DRUG EFFECTS; GRAFT OCCLUSION, VASCULAR; MIDDLE AGED; RENAL REPLACEMENT THERAPY; THROMBOSIS; VASCULAR PATENCY;

AGED; CENTRAL VENOUS CATHETERS; FEMALE; FIBRINOLYTIC AGENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 84940613147     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12462     Document Type: Article

References (23)

1. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
2. Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial 2004;17:310-319.
3. Lugon JR. Doença Renal Crônica no Brasil: um problema de saúde público. J Bras Nefrol 2004;31(Suppl. 1):2-5.
4. Suchoki PV, Conlon PJ, Knelson MH, Harland RC, Schwab SJ. Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of HD catheters malfunction. Am J Kidney Dis 1996;28:379-386.
5. Crain MR, Mewissen MW, Ostrowski GJ, Paz-Fumagalli R, Beres RA, Wertz RA. Fibrin sleeve stripping for salvage of failing hemodialysis catheters: technique and initial results. Radiology 1996;198:41-44.
6. Timoney JP, Malkin MG, Leone DM, etal. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002;20:317-324.
7. Chan MR, Yevzlin AS. Tunneled dialysis catheters: recent trends and future directions. Adv Chronic Kidney Dis 2009;16:386-395.
8. Lee T, Barker J, Allon M. Tunneled catheters in hemodialysis patients: reasons and subsequente outcomes. Am J Kidney Dis 2005;46:501-508.
9. Liangos O, Gul A, Madias NE, Jaber BL. Long-term management of the tunneled venous catheter. Semin Dial 2006;19:158-164.
10. Deitcher SR, Fesen MR, Kiprof PM, etal. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002;20:317-324.
11. NKF-K/DOQI clinical practice guidelines for vascular access: update 2000. Am J Kidney Dis 2001;37(Suppl. 1):S137-181.
12. Genentech Inc. Activase (Alteplase, Recombinant) [Product Information Brochure]. South San Francisco, CA: Genentech, Inc., 1999.
13. Ponec D, Irwin D, Haire WD, etal. Recombinant tissue plasminogen activator (alteplase) for restoration of fl ow in occluded central venous access devices: a double-blind placebo-controlled trial-the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001;12:951-955.
14. Davis SN, Vermeulen L, Schwartz BS, etal. Activity and dosage of alteplase dilution for clearing occlusions of venous-acces devices. Am J Health Syst Pharm 2000;57:1039-1045.
15. Schon D, Whittman D. Managing the complications of long-term tunneled dialysis catheters. Semin Dial 2003;16:314-322.
16. Haire WD, Atkinson JB, Stephens LC, etal. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blind randomized trial. Thromb Haemost 1994;72:547-549.
17. Vercaigne LM, Zacharias J, Bernstein KN. Alteplase for blood flow restoration in hemodialysis catheters: a multicenter, randomized, prospective study comparing "dwell" versus "push" administration. Clin Nephrol 2012;78:287-296.
18. Goldman J, Fishbane S, Oliver MJ, Blaney M, Jacobs JR, Begelman SM. Tenecteplase for the improvement of blood flow rate in dysfunctional hemodialysis catheters. Clin Nephrol 2012;77:55-61.
19. Tumlin J, Goldman J, Spiegel DM, etal. A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3. Clin J Am Soc Nephrol 2012;5:631-636.
20. Hemmelgarn BR, Moist LM, Lok CE, etal. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med 2012;364:303-312.
21. Hilleman D, Campbell J. Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review. Pharmacotherapy 2011;31:1031-1040.
22. Mendes ML, de Castro JH, Barreti P, Silva TN, Ponce D. Effective use of alteplase for occluded tunneled venous catheter in hemodialysis patients. Artif Organs 2014;38:399-403.
23. Ponec D, Irwin D, Haire WD, Hill PA, McCluskey ER, COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double blind placebo-controlled trial-the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Inter Radiol 2001;12:951-955.